Base de dados : MEDLINE
Pesquisa : D06.472.699.327.740.320 [Categoria DeCS]
Referências encontradas : 26226 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2623 ir para página                         

  1 / 26226 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29175396
[Au] Autor:Wang F; Liu F; Chen W; Xu R; Wang W
[Ad] Endereço:School of Biological Science, Luoyang Normal University, Luoyang, 471022, China; Cold Water Fish Breeding Engineering Technology Research Center of Henan Province, Luoyang, 471022, China. Electronic address: wangfan7677@163.com.
[Ti] Título:Effects of triclosan (TCS) on hormonal balance and genes of hypothalamus-pituitary- gonad axis of juvenile male Yellow River carp (Cyprinus carpio).
[So] Source:Chemosphere;193:695-701, 2018 Feb.
[Is] ISSN:1879-1298
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Triclosan (TCS) is a broad spectrum antimicrobial agent which has been widely dispersed and determinated in the aquatic environment. However, the effects of TCS on reproductive endocrine in male fish are poorly understood. In this study, male Yellow River carp (Cyprinus carpio) were exposed to 0, 1/5, 1/10 and 1/20 LC (96 h LC of TCS to carp) TCS under semi-static conditions for 42 d. Vitellogenin (Vtg), 17ß-estradiol (E ), testosterone(T), gonadotropin (GtH), and gonadotropin-releasing hormone (GnRH) levels were measured by enzyme-linked immunosorbent assay (ELISA). Meanwhile, we also examined the mRNA expressions of aromatase, GtHs-ß, GnRH, estrogen receptor (Er), and androgen receptor (Ar) by quantitative Real-time Polymerase Chain Reaction (qRT-PCR). TCS induced Vtg levels of hepatopancreas, E levels of serum, and inhibited Ar and Er mRNA levels, suggesting that the induction of Vtg production by TCS was indirectly caused by non-Er pathways. TCS-induced Vtg levels by interfering with the reproductive axis at plenty of latent loci of male carps: (a) TCS exposure increased the aromatase mRNA expression of hypothalamus and gonad aromatase, consequently increasing serum concentrations of E to induce Vtg in hepatopancreas; (b) TCS treatment changed GtH-ß and GnRH mRNA expression and secretion, causing the disturbance of reproductive endocrine; (c) TCS exposure decreased Ar mRNA levels, indicating potential Ar-mediated antiandrogen action. These mechanisms showed that TCS may induce Vtg production in male carp by non-Er-mediated pathways.
[Mh] Termos MeSH primário: Carpas/metabolismo
Triclosan/toxicidade
Poluentes Químicos da Água/toxicidade
[Mh] Termos MeSH secundário: Animais
Anti-Infecciosos/toxicidade
Aromatase/genética
Sistema Endócrino/efeitos dos fármacos
Ensaio de Imunoadsorção Enzimática
Estradiol/análise
Hormônio Liberador de Gonadotropina/análise
Hormônio Liberador de Gonadotropina/genética
Gônadas/enzimologia
Gônadas/metabolismo
Hepatopâncreas/metabolismo
Hormônios/metabolismo
Hipotálamo/metabolismo
Masculino
Hipófise/metabolismo
RNA Mensageiro/análise
Reação em Cadeia da Polimerase em Tempo Real
Receptores Estrogênicos/genética
Reprodução/efeitos dos fármacos
Testosterona/análise
Vitelogeninas/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Anti-Infective Agents); 0 (Hormones); 0 (RNA, Messenger); 0 (Receptors, Estrogen); 0 (Vitellogenins); 0 (Water Pollutants, Chemical); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone); 4NM5039Y5X (Triclosan); 4TI98Z838E (Estradiol); EC 1.14.14.1 (Aromatase); EC 1.14.14.1 (CYP19A1 protein, human)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  2 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29395088
[Au] Autor:Loganathan K; Moriya S; Parhar IS
[Ad] Endereço:Brain Research Institute, Monash University Malaysia, Jalan Lagoon Selatan, Bandar Sunway, Selangor, 47500, Malaysia.
[Ti] Título:Trek2a regulates gnrh3 expression under control of melatonin receptor Mt1 and α -adrenoceptor.
[So] Source:Biochem Biophys Res Commun;496(3):927-933, 2018 02 12.
[Is] ISSN:1090-2104
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Gonadotrophin-releasing hormone (GnRH) expression is associated with the two-pore domain potassium ion (K ) channel-related K (TREK) channel trek2a expression and melatonin levels. We aimed to investigate correlation of trek2a expression with gnrh3 expression, and regulatory mechanisms of trek2a expression by the melatonin receptor Mt1 and α -adrenoceptor which are regulated by melatonin. trek2a specific siRNA, Mt1 antagonist luzindole and α -adrenoceptor antagonist prazosin were administered into the adult zebrafish brain and gene expressions were examined by real-time PCR. trek2a specific siRNA administration significantly reduced expression levels of trek2a, gnrh3 and mt1. Luzindole administration suppressed trek2a and gnrh3 expressions. Prazosin administration reduced trek2a and gnrh3 expressions. It is suggested that Trek2a regulates gnrh3 expression under the control of Mt1 and α -adrenoceptor.
[Mh] Termos MeSH primário: Encéfalo/metabolismo
Hormônio Liberador de Gonadotropina/metabolismo
Melatonina/metabolismo
Canais de Potássio de Domínios Poros em Tandem/metabolismo
Ácido Pirrolidonocarboxílico/análogos & derivados
Receptor MT1 de Melatonina/metabolismo
Receptores Adrenérgicos alfa 2/metabolismo
Proteínas de Peixe-Zebra/metabolismo
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Regulação da Expressão Gênica/fisiologia
Masculino
Ácido Pirrolidonocarboxílico/metabolismo
Transdução de Sinais/fisiologia
Peixe-Zebra
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (K(2P)10.1 protein, zebrafish); 0 (Potassium Channels, Tandem Pore Domain); 0 (Receptor, Melatonin, MT1); 0 (Receptors, Adrenergic, alpha-2); 0 (Zebrafish Proteins); 0 (gonadotropin-releasing hormone-III); 33515-09-2 (Gonadotropin-Releasing Hormone); JL5DK93RCL (Melatonin); SZB83O1W42 (Pyrrolidonecarboxylic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180204
[St] Status:MEDLINE


  3 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29197784
[Au] Autor:Banerjee S; Chaturvedi CM
[Ad] Endereço:Department of Zoology, Banaras Hindu University, Varanasi 221005, India.
[Ti] Título:Simulated photoperiod influences testicular activity in quail via modulating local GnRHR-GnIHR, GH-R, Cnx-43 and 14-3-3.
[So] Source:J Photochem Photobiol B;178:412-423, 2018 Jan.
[Is] ISSN:1873-2682
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:The hypothalamo-hypophyseal-gonadal axis mediated differential photosexual responses in quail kept under different simulated photoperiodic conditions have been studied in details. Local testicular GnRH-GnIH and their receptor system has been hypothesized to be modulated in quail showing different photo-sexual responses and thus influence the testicular activity and steroidogenesis through local (paracrine and autocrine) action. To validate this hypothesis, we studied the expression of gonadotropin releasing hormone receptor (GnRH-R), gonadotropin inhibiting hormone receptor (GnIH-R) mRNA, growth hormone receptor (GH-R), proliferating cell nuclear antigen (PCNA), 14-3-3, Connexin-43 (Cnx-43), steroidogenic factor-1 (SF-1), Steroidogenic Acute Regulatory protein (StAR), steroidogenic enzyme (3ß HSD) in testis as well as androgen receptor (AR) in testis and epididymis of photosensitive (PS), scotorefractory (SR), photorefractory (PR) and scotosensitive (SS) quail. Experimental findings clearly indicate the increased expression of GnIH-R mRNA and suppression of GnRH-R, GH-R, PCNA, 14-3-3, Connexin-43, SF-1, StAR, 3ß HSD in testis as well as AR in testis and epididymis of PR and SS quail, while PS and SR quail exhibited the opposite results i.e., significantly decreased expression of GnIH-R mRNA and increased expression of GnRH-R, GH-R, PCNA, 14-3-3, Cnx-43, SF-1, StAR, 3ß HSD in testis as well as AR in testis and epididymis. The significantly increased intra-testicular testosterone has been observed in the PS and SR quail while, PR and SS quail showed opposite results. Hence, we conclude that PS and SR quail showed significantly increased testicular activity and steroidogenesis while opposite pattern was observed in PR and SS quail.
[Mh] Termos MeSH primário: Proteínas 14-3-3/metabolismo
Conexina 43/metabolismo
Hormônio Liberador de Gonadotropina/metabolismo
Receptores LHRH/metabolismo
Testículo/metabolismo
[Mh] Termos MeSH secundário: Proteínas 14-3-3/genética
Animais
Conexina 43/genética
Epididimo/metabolismo
Epididimo/patologia
Hormônio Liberador de Gonadotropina/genética
Masculino
Microscopia Confocal
Fotoperíodo
Antígeno Nuclear de Célula em Proliferação/genética
Antígeno Nuclear de Célula em Proliferação/metabolismo
Codorniz
Receptores Androgênicos/genética
Receptores Androgênicos/metabolismo
Receptores LHRH/genética
Fator Esteroidogênico 1/genética
Fator Esteroidogênico 1/metabolismo
Testículo/patologia
Testosterona/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (14-3-3 Proteins); 0 (Connexin 43); 0 (Proliferating Cell Nuclear Antigen); 0 (Receptors, Androgen); 0 (Receptors, LHRH); 0 (Steroidogenic Factor 1); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171204
[St] Status:MEDLINE


  4 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29331479
[Au] Autor:Zhao C; Zhu W; Yin S; Cao Q; Zhang H; Wen X; Zhang G; Xie W; Chen S
[Ad] Endereço:College of Life Sciences, Key Laboratory of Biodiversity and Biotechnology of Jiangsu Province, Nanjing Normal University, Nanjing, Jiangsu 210023, China; Co-Innovation Center for Marine Bio-Industry Technology of Jiangsu Province, Lianyungang, Jiangsu 222005, China.
[Ti] Título:Molecular characterization and expression of Piwil1 and Piwil2 during gonadal development and treatment with HCG and LHRH-A in Odontobutis potamophila.
[So] Source:Gene;647:181-191, 2018 Mar 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Piwi proteins play an important regulatory role in germ cell division during gametogenesis and gonad development. In order to understand the function of Piwi genes in the reproductive process of the dark sleeper, we identified and characterized Piwil1 and Piwil2 from gonad tissue. The tissue distribution demonstrated that Piwils were highly expressed in the gonad of the dark sleeper. During gonad development, higher expression was observed in stage I of both the testes and ovaries than in subsequent stages at mRNA and protein levels. The results of immunohistochemistry demonstrated that Piwils were predominantly distributed in the spermatogonia, spermatocytes, and early oocytes. When treated with the HPG axis hormone (HCG and LHRH-A2), the expression of Piwils was significantly decreased in the testes and ovaries at mRNA and protein levels. All of these results indicated that Piwils play a vital role in gonad development and gametogenesis. Our findings provide valuable evidence to further clarify the underlying modulation mechanism of Piwils in teleosts.
[Mh] Termos MeSH primário: Proteínas Argonauta/genética
Gonadotropina Coriônica/farmacologia
Regulação da Expressão Gênica no Desenvolvimento/genética
Hormônio Liberador de Gonadotropina/farmacologia
Gônadas/efeitos dos fármacos
Perciformes/genética
[Mh] Termos MeSH secundário: Sequência de Aminoácidos
Animais
Sequência de Bases
Gametogênese/efeitos dos fármacos
Gametogênese/genética
Regulação da Expressão Gênica no Desenvolvimento/efeitos dos fármacos
Masculino
Oócitos/efeitos dos fármacos
Filogenia
RNA Mensageiro/genética
Espermatócitos/efeitos dos fármacos
Espermatogônias/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Argonaute Proteins); 0 (Chorionic Gonadotropin); 0 (RNA, Messenger); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180115
[St] Status:MEDLINE


  5 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27771155
[Au] Autor:Sükür YE; Özmen B; Özdemir ED; Seval MM; Kalafat E; Sönmezer M; Berker B; Aytaç R; Atabekoglu CS
[Ad] Endereço:Department of Obstetrics and Gynecology, Ankara University School of Medicine, Kadin Hastaliklari ve Dogum AD, 06100 Cebeci, Ankara, Turkey.
[Ti] Título:Final oocyte maturation with two different GnRH agonists in antagonist co-treated cycles at risk of ovarian hyperstimulation syndrome.
[So] Source:Reprod Biomed Online;34(1):5-10, 2017 Jan.
[Is] ISSN:1472-6491
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Triptorelin 0.2 mg and leuprolide 1 mg subcutaneous injections for triggering final follicular maturation were compared in patients with a high risk for ovarian hyperstimulation syndrome (OHSS). Infertile patients treated with GnRH antagonist protocol between January 2014 and March 2016 were recruited. Patients with high serum oestradiol levels on HCG day (>3000 pg/ml) indicating a risk of OHSS consisted of the study groups (A and B). Patients with serum oestradiol levels less than 3000 pg/ml consisted of the control group (C). A single injection of 0.2 mg triptorelin, 1 mg leuprolide and 10000 IU HCG were administered for final oocyte triggering in groups A (n = 63), B (n = 74) and C (n = 131), respectively. Demographic parameters were comparable between the groups. No cases of severe or moderate OHSS occurred in any group. The clinical pregnancy rates were 31.7%, 37.8% and 32.8% in groups A, B and C, respectively. Both injections had comparable efficacy in clinical outcome and OHSS risk. Regardless of preferred drug, GnRH agonist trigger for final oocyte maturation seems to be safe for patients with high OHSS risk, and can be safely used in fresh embryo transfer cycles.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/agonistas
Hormônio Liberador de Gonadotropina/antagonistas & inibidores
Oócitos/citologia
Síndrome de Hiperestimulação Ovariana/tratamento farmacológico
[Mh] Termos MeSH secundário: Adolescente
Adulto
Estradiol/sangue
Feminino
Antagonistas de Hormônios/uso terapêutico
Seres Humanos
Infertilidade Feminina/terapia
Infertilidade Masculina/terapia
Leuprolida/administração & dosagem
Masculino
Oócitos/efeitos dos fármacos
Oogênese
Indução da Ovulação
Gravidez
Taxa de Gravidez
Estudos Retrospectivos
Risco
Injeções de Esperma Intracitoplásmicas
Pamoato de Triptorrelina/administração & dosagem
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Hormone Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone); 4TI98Z838E (Estradiol); 57773-63-4 (Triptorelin Pamoate); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:161025
[St] Status:MEDLINE


  6 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29187457
[Au] Autor:Chen MY; Chen YY; Tsai HT; Tzai TS; Chen MC; Tsai YS
[Ad] Endereço:Department of Urology, Madou Sin-Lau Hospital, Sin-Lau Medical Foundation, the Presbyterian Church in Taiwan, Tainan, Taiwan, R.O.C.
[Ti] Título:Transdermal Delivery of Luteinizing Hormone-releasing Hormone with Chitosan Microneedles: A Promising Tool for Androgen Deprivation Therapy.
[So] Source:Anticancer Res;37(12):6791-6797, 2017 12.
[Is] ISSN:1791-7530
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:Long-term administration of luteinizing hormone-releasing hormone analogs (LHRHa) is the main type of androgen-deprivation therapy (ADT) for lethal prostate cancer. A fully insertable microneedle system, composed of embeddable chitosan microneedles and a dissolvable polyvinyl alcohol/polyvinyl pyrrolidone supporting array, was developed for sustained delivery of LHRHa to the skin. A porcine cadaver skin test showed that chitosan microneedles can be fully embedded within the skin and microneedle-created micropores reseal within 7 days. The measured LHRHa loading amount was 73.3±2.8 µg per microneedle patch. After applying goserelin-containing microneedles to mice, serum LH levels increased initially and then declined below baseline at day 7. In contrast, serum testosterone levels increased to reach a peak at day 14 and then declined to a castration level at day 21. Additionally, such a castration level was maintained for 2 weeks. Therefore, transdermal delivery of goserelin with embeddable chitosan microneedles can produce a castrated state in mice. Such a system is a promising, feasible means of delivering ADT.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/administração & dosagem
Quitosana/química
Sistemas de Liberação de Medicamentos/métodos
Hormônio Liberador de Gonadotropina/administração & dosagem
Agulhas
[Mh] Termos MeSH secundário: Administração Cutânea
Antagonistas de Androgênios/química
Antagonistas de Androgênios/farmacocinética
Animais
Antineoplásicos Hormonais/administração & dosagem
Antineoplásicos Hormonais/química
Antineoplásicos Hormonais/farmacocinética
Hormônio Liberador de Gonadotropina/química
Hormônio Liberador de Gonadotropina/farmacocinética
Gosserrelina/administração & dosagem
Gosserrelina/química
Gosserrelina/farmacocinética
Seres Humanos
Hormônio Luteinizante/sangue
Masculino
Camundongos Endogâmicos ICR
Pele/metabolismo
Suínos
Testosterona/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Antineoplastic Agents, Hormonal); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone); 9002-67-9 (Luteinizing Hormone); 9012-76-4 (Chitosan)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171219
[Lr] Data última revisão:
171219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171201
[St] Status:MEDLINE


  7 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29036173
[Au] Autor:de Milliano I; Twisk M; Ket JC; Huirne JA; Hehenkamp WJ
[Ad] Endereço:Department of Obstetrics and Gynecology, VU Medical Center, Amsterdam, The Netherlands.
[Ti] Título:Pre-treatment with GnRHa or ulipristal acetate prior to laparoscopic and laparotomic myomectomy: A systematic review and meta-analysis.
[So] Source:PLoS One;12(10):e0186158, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Myomectomy has potential risks of complications. To reduce these risks, medical pre-treatment can be applied to reduce fibroid size and thereby potentially decrease intra-operative blood loss, the need for blood transfusion and emergency hysterectomy. The aim of this systematic review and meta-analysis is to study the effectiveness of medical pre-treatment with Gonadotropin-releasing hormone agonists (GnRHa) or ulipristal acetate prior to laparoscopic or laparotomic myomectomy on intra-operative and post-operative outcomes. METHODS: We performed an extensive search in Embase.com, Wiley/Cochrane Library and PubMed in accordance with the Prisma guidelines. All studies published as full papers in peer reviewed journals using GnRHa or ulipristal acetate as medical pre-treatment independent of route of administration or dosage before laparotomic or laparoscopic myomectomy were included. The primary outcome was duration of surgery. Secondary outcomes were duration of enucleation, blood loss, degree of difficulty of surgery, identification of cleavage planes, proportion of vertical incisions, conversion rate, frequency of blood transfusions, post-operative complications, duration of hospital stay, frequency of recurrence of fibroids, frequency of uterine adhesions, recovery time and quality of life. No language restrictions were applied. Meta-analysis were performed where possible. FINDINGS: Twenty-three studies were included. In laparotomic myomectomy, pre-treatment with GnRHa decreases intra-operative blood loss with 97.39ml (95% CI -111.80 to -82.97) compared to no pre-treatment or placebo. Pre-treatment with GnRHa before laparoscopic myomectomies also shows a reduction in intra-operative blood loss by 23.03ml (95% CI -40.79 to -5.27) and in the frequency of blood transfusions (OR 0.17, 95% CI 0.05 to 0.55) compared to no pre-treatment. Only two retrospective cohort studies reported on pre-treatment with ulipristal acetate compared to no pre-treatment before laparoscopic myomectomy showing a statistically significant reduction in intra-operative blood loss, duration of surgery and frequency of blood transfusions after pre-treatment with ulipristal acetate. CONCLUSION: Administration of GnRHa prior to laparotomic myomectomy reduces blood loss and might decrease uterine adhesion formation. Pre-treatment with GnRHa before laparoscopic myomectomy reduces blood loss, the frequency of blood transfusions and might increase recurrence rate of fibroids, however it should be taken into account that some results are mainly based on cohort studies. Other pre-treatment agent ulipristal acetate has not been investigated sufficiently for relevant surgical outcomes.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/análogos & derivados
Laparoscopia
Laparotomia
Norpregnadienos/administração & dosagem
Substâncias Protetoras/administração & dosagem
Miomectomia Uterina
[Mh] Termos MeSH secundário: Feminino
Hormônio Liberador de Gonadotropina/administração & dosagem
Seres Humanos
Complicações Pós-Operatórias/prevenção & controle
Cuidados Pré-Operatórios
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Nm] Nome de substância:
0 (Norpregnadienes); 0 (Protective Agents); 33515-09-2 (Gonadotropin-Releasing Hormone); 79561-22-1 (LHRH, Ala(6)-Gly(10)-ethylamide-); YF7V70N02B (ulipristal acetate)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171017
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0186158


  8 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29017178
[Au] Autor:Haque R; UlcickasYood M; Xu X; Cassidy-Bushrow AE; Tsai HT; Keating NL; Van Den Eeden SK; Potosky AL
[Ad] Endereço:Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA 91101, USA.
[Ti] Título:Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study.
[So] Source:Br J Cancer;117(8):1233-1240, 2017 Oct 10.
[Is] ISSN:1532-1827
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: As androgen deprivation therapy (ADT) is increasingly being used in men with localised prostate cancer, our goal was to examine the association between ADT and the risk of cardiovascular disease (CVD). METHODS: We conducted a prospective cohort study using records of a large health-care system in California. The study included men with newly diagnosed localised prostate cancer (1998-2008) who initially underwent active surveillance (N=7637) and were followed through 2010. We examined 10 individual CVD outcomes. Cox proportional hazard models incorporated time-varying treatment variables and controlled for race/ethnicity, age, and tumour characteristics, recurrence risk, CVD medication use, and CVD risk factors. RESULTS: Of the 7637 subjects, nearly 30% were exposed to ADT. In the multivariable analyses, ADT was associated with an increased risk of heart failure (adjusted HR=1.81, 95% CI 1.40-2.32) in men without preexisting CVD. Elevated risks of arrhythmia (adjusted HR=1.44, 95% CI 1.02-2.01), and conduction disorder (adjusted HR=3.11, 95% CI 1.22, 7.91) were only observed among patients with preexisting CVD. CONCLUSIONS: In men with clinically localised prostate cancer who were initially under active surveillance, ADT was associated with a greater risk of heart failure in men without any preexisting CVD. We also found an increased risk of arrhythmia and conduction disorder in men with preexisting CVD. This study provides the basis for identifying high-risk men treated with ADT who might benefit from regular cardiac monitoring and lifestyle modification recommendations.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Antineoplásicos Hormonais/uso terapêutico
Arritmias Cardíacas/epidemiologia
Insuficiência Cardíaca/epidemiologia
Neoplasias da Próstata/tratamento farmacológico
[Mh] Termos MeSH secundário: Idoso
Anilidas/uso terapêutico
California/epidemiologia
Doenças Cardiovasculares/epidemiologia
Estudos de Coortes
Flutamida/uso terapêutico
Hormônio Liberador de Gonadotropina/agonistas
Gosserrelina/uso terapêutico
Seres Humanos
Imidazolidinas/uso terapêutico
Leuprolida/uso terapêutico
Masculino
Meia-Idade
Análise Multivariada
Gradação de Tumores
Nitrilos/uso terapêutico
Modelos de Riscos Proporcionais
Estudos Prospectivos
Neoplasias da Próstata/epidemiologia
Neoplasias da Próstata/patologia
Fatores de Risco
Compostos de Tosil/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 0 (Anilides); 0 (Antineoplastic Agents, Hormonal); 0 (Imidazolidines); 0 (Nitriles); 0 (Tosyl Compounds); 0F65R8P09N (Goserelin); 33515-09-2 (Gonadotropin-Releasing Hormone); 51G6I8B902 (nilutamide); 76W6J0943E (Flutamide); A0Z3NAU9DP (bicalutamide); EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171110
[Lr] Data última revisão:
171110
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171011
[St] Status:MEDLINE
[do] DOI:10.1038/bjc.2017.280


  9 / 26226 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28977601
[Au] Autor:Garcia JP; Guerriero KA; Keen KL; Kenealy BP; Seminara SB; Terasawa E
[Ad] Endereço:Wisconsin National Primate Research Center, Madison, Wisconsin 53715.
[Ti] Título:Kisspeptin and Neurokinin B Signaling Network Underlies the Pubertal Increase in GnRH Release in Female Rhesus Monkeys.
[So] Source:Endocrinology;158(10):3269-3280, 2017 Oct 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Loss-of-function or inactivating mutations in the genes coding for kisspeptin and its receptor (KISS1R) or neurokinin B (NKB) and the NKB receptor (NK3R) in humans result in a delay in or the absence of puberty. However, precise mechanisms of kisspeptin and NKB signaling in the regulation of the pubertal increase in gonadotropin-releasing hormone (GnRH) release in primates are unknown. In this study, we conducted a series of experiments infusing agonists and antagonists of kisspeptin and NKB into the stalk-median eminence, where GnRH, kisspeptin, and NKB neuroterminal fibers are concentrated, and measuring GnRH release in prepubertal and pubertal female rhesus monkeys. Results indicate that (1) similar to those previously reported for GnRH stimulation by the KISS1R agonist (i.e., human kisspeptin-10), the NK3R agonist senktide stimulated GnRH release in a dose-responsive manner in both prepubertal and pubertal monkeys; (2) the senktide-induced GnRH release was blocked in the presence of the KISS1R antagonist peptide 234 in pubertal but not prepubertal monkeys; and (3) the kisspeptin-induced GnRH release was blocked in the presence of the NK3R antagonist SB222200 in the pubertal but not prepubertal monkeys. These results are interpreted to mean that although, in prepubertal female monkeys, kisspeptin and NKB signaling to GnRH release is independent, in pubertal female monkeys, a reciprocal signaling mechanism between kisspeptin and NKB neurons is established. We speculate that this cooperative mechanism by the kisspeptin and NKB network underlies the pubertal increase in GnRH release in female monkeys.
[Mh] Termos MeSH primário: Hormônio Liberador de Gonadotropina/secreção
Kisspeptinas/fisiologia
Macaca mulatta/fisiologia
Neurocinina B/fisiologia
Maturidade Sexual/fisiologia
Transdução de Sinais/fisiologia
[Mh] Termos MeSH secundário: Animais
Feminino
Kisspeptinas/agonistas
Kisspeptinas/antagonistas & inibidores
Kisspeptinas/farmacologia
Eminência Mediana/efeitos dos fármacos
Neurocinina B/agonistas
Neurocinina B/antagonistas & inibidores
Neurônios/metabolismo
Fragmentos de Peptídeos/farmacologia
Quinolinas/farmacologia
Receptores Acoplados a Proteínas-G/agonistas
Receptores Acoplados a Proteínas-G/antagonistas & inibidores
Receptores de Kisspeptina-1
Receptores da Neurocinina-3/agonistas
Transdução de Sinais/efeitos dos fármacos
Substância P/análogos & derivados
Substância P/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (KISS1 protein, human); 0 (KISS1R protein, human); 0 (Kisspeptins); 0 (Peptide Fragments); 0 (Quinolines); 0 (Receptors, G-Protein-Coupled); 0 (Receptors, Kisspeptin-1); 0 (Receptors, Neurokinin-3); 0 (SB 222200); 106128-89-6 (senktide); 33507-63-0 (Substance P); 33515-09-2 (Gonadotropin-Releasing Hormone); 86933-75-7 (Neurokinin B)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171116
[Lr] Data última revisão:
171116
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:171005
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00500


  10 / 26226 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28968166
[Au] Autor:Chen DY; See LC; Liu JR; Chuang CK; Pang ST; Hsieh IC; Wen MS; Chen TH; Lin YC; Liaw CC; Hsu CL; Chang JW; Kuo CF; Huang WK
[Ad] Endereço:Dong-Yi Chen, Lai-Chu See, Jia-Rou Liu, Cheng-Keng Chuang, See-Tong Pang, I-Chang Hsieh, Ming-Shien Wen, Yung-Chang Lin, Chuang-Chi Liaw, Cheng-Lung Hsu, John Wen-Cheng Chang, Chang-Fu Kuo and Wen-Kuan Huang, Chang Gung Memorial Hospital, Linkou, Chang Gung University College of Medicine; Taoyuan; T
[Ti] Título:Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
[So] Source:J Clin Oncol;35(32):3697-3705, 2017 Nov 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose Our aim was to determine whether cardiovascular (CV) risk in patients with prostate cancer (PCa) differs between those who receive androgen-deprivation therapy by surgical castration and those who receive gonadotropin-releasing hormone agonist (GnRHa) therapy. Patients and Methods By using the Taiwan National Health Insurance Research Database, we analyzed data from 14,715 patients with PCa diagnosed from January 1, 1997, through December 31, 2011. The patients were treated with bilateral orchiectomy or GnRHa therapy. We used inverse probability of treatment weighting with propensity scores to adjust for the imbalance in covariate baseline values between these two groups. Cox regression models were used to identify risk factors for myocardial infarction (MI), ischemic stroke (IS), and cardiac-related complications. Results Overall, 3,578 patients with PCa (24.3%) underwent bilateral orchiectomy and 11,137 patients (75.7%) received GnRHa therapy. Both groups had a similar risk of CV ischemic events (ie, MI or IS; hazard ratio, 1.16; 95% CI, 0.97 to 1.38) during a median follow-up time of 3.3 years. However, during the first 1.5 years of follow-up, there were higher CV ischemic events in the orchiectomy group than in the GnRHa group (hazard ratio, 1.40; 95% CI, 1.04 to 1.88), particularly in patients who were ≥ 65 years of age, had hypertension, had a Charlson comorbidity index score ≥ 3, and had a previous history of MI, IS, or coronary heart disease. Conclusion Compared with bilateral orchiectomy, use of GnRHa does not increase the risk of CV ischemic events in patients with PCa. Nonetheless, orchiectomy is associated with higher rates of CV ischemic events in older patients and those with a history of CV comorbidities within 1.5 years of initiating androgen-deprivation therapy. These findings can help clinicians decide on the optimal castration strategy for individual patients.
[Mh] Termos MeSH primário: Antagonistas de Androgênios/uso terapêutico
Isquemia Encefálica/epidemiologia
Doença das Coronárias/epidemiologia
Hormônio Liberador de Gonadotropina/agonistas
Infarto do Miocárdio/epidemiologia
Orquiectomia/efeitos adversos
Neoplasias da Próstata/tratamento farmacológico
Neoplasias da Próstata/cirurgia
Acidente Vascular Cerebral/epidemiologia
[Mh] Termos MeSH secundário: Idoso
Antagonistas de Androgênios/efeitos adversos
Terapia Combinada
Seres Humanos
Incidência
Masculino
Meia-Idade
Risco
Taiwan/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgen Antagonists); 33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171113
[Lr] Data última revisão:
171113
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2016.71.4204



página 1 de 2623 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde